Johnson & Johnson (NYSE:JNJ) is one of the largest and most prolific drugmakers, and its stock is a staple in dividend portfolios.

However, patent expiration has created revenue headwinds that the company will need to overcome with newly launched drugs, especially as one of its top-selling treatments loses patent protection in Europe in 2015. Dividend investors are also right to wonder whether Johnson & Johnson's profitability, which has slipped in recent years due to higher spending, threatens its dividend strategy.

In the following slideshow, you'll learn how Johnson & Johnson is navigating the patent cliff for revenue growth, see what may be in store for its margins, and discover how the company stacks up to competitors such Merck and Bristol-Myers Squibb when it comes to dividend payouts.